ADVFN - Advanced Financial Network.
HOME» NYSE » M » MRK Stock Price » MRK Stock News

Merck Share News

 Merck & Co., Stock Price
MRK Stock Price
 Merck & Co., Stock Chart
MRK Stock Chart
 Merck & Co., Stock News
MRK Stock News
 Merck & Co., Company Information
MRK Company Information
 Merck & Co., Stock Trades
MRK Stock Trades

Cardiome To Slash Workforce by 85% on End of Merck's Oral Development Program

By Chelsea Stevenson Cardiome Pharma Corp. (CRME) plans to reduce its workforce by about 85% in response to the termination of Merck & Co.'s (MRK) developing vernakalant oral program. All positions focused on internal research and certain supporting functions will be eliminated, Canadian-based Cardiome Pharma said. The reductions will result in up to $5 million in severance charges over the remainder of the year. In March, Cardiome's partner Merck discontinued its development of its oral vernakalant drug, which prevented atrial fibrillation. Cardiome had said it was disappointed with Merck's decision. Interim Chief Executive Dr. William Hunter said the board regrets the effects of the decision. Dr. Hunter replaced former Chief Executive Doug Janzen, who left the company last week. Cardiome Pharma reported a slightly narrower loss for its first quarter, citing clinical development efforts and pre-clinical research project expenditures. The latest quarter's loss also includes employee termination charges. The company said it will issue a further progress report in mid-August to its shareholders. Shares were off 2.3% to 43 cents in recent trading and have dropped 84% this year. Write to Chelsea Stevenson at chelsea.stevenson@dowjones.com

Stock News for Merck (MRK)
DateTimeHeadline
07/22/201607:00:00Data for Merck's Investigational Once-Daily Formulation of ISENTRESS®...
07/21/201617:00:00Merck Animal Health Receives FDA Approval of BRAVECTO® (fluralaner...
07/21/201616:30:00Merck Provides Regulatory Update on Biologics Licensing Application...
07/18/201612:08:00MARKET SNAPSHOT: Dow On Track For Record Closing High As Tech...
07/18/201602:10:00China's Food and Drug Administration Approves GlaxoSmithKline's...
07/13/201603:03:00Business Watch -- WSJ
07/12/201615:20:00Merck & Co. to Cut Research Jobs at Three East-Coast Sites
07/12/201615:08:00Merck & Co. Cutting Drug Research Jobs at 3 East-Coast Sites...
07/12/201614:46:00Merck & Co. Cutting Drug Research Jobs at 3 East-Coast Sites...
07/05/201612:57:50Statement of Changes in Beneficial Ownership (4)
07/05/201612:57:21Statement of Changes in Beneficial Ownership (4)
07/02/201603:03:00Merck to Buy Control Of Animal-Health Firm -- WSJ
07/01/201615:20:00Merck to Buy Brazilian Animal-Health Company
07/01/201615:09:00Merck to Buy Brazilian Animal-Health Company for $400 Million
07/01/201613:15:08Statement of Changes in Beneficial Ownership (4)
07/01/201613:15:08Statement of Changes in Beneficial Ownership (4)
07/01/201613:15:08Statement of Changes in Beneficial Ownership (4)
07/01/201613:15:07Statement of Changes in Beneficial Ownership (4)
07/01/201613:15:07Statement of Changes in Beneficial Ownership (4)
07/01/201613:14:37Statement of Changes in Beneficial Ownership (4)

Merck and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad